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ABSTRACT
Introduction: Hemolytic disease of the fetus and newborn (HDFN) occurs when fetal and neonatal
erythroid cells are destroyed by maternal erythrocyte alloantibodies, it leads to anemia and hydrops in
the fetus, and hyperbilirubinemia and kernicterus in the newborn. Postnatal care consists of intensive
phototherapy and exchange transfusions to treat severe hyperbilirubinemia and top-up transfusions to
treat early and late anemia. Other postnatal complications have been reported such as thrombocyto-
penia, iron overload and cholestasis requiring specific management.
Areas covered: This review focusses on the current neonatal management and outcome of hemolytic
disease and discusses postnatal treatment options as well as literature on long-term neurodevelop-
mental outcome.
Expert commentary: Despite major advances in neonatal management, multiple issues have to be
addressed to optimize postnatal management and completely eradicate kernicterus. Except for strict
adherence to guidelines, improvement could be achieved by clarifying the epidemiology and patho-
physiology of HDFN. Several pharmacotherapeutic agents should be further researched as alternative
treatment options in hyperbilirubinemia, including immunoglobulins, albumin, phenobarbital, metallo-
porphyrins, zinc, clofibrate and prebiotics. Larger trials are warranted to evaluate EPO, folate and
vitamin E in neonates. Long-term follow-up studies are needed in HDFN, especially on thrombocyto-
penia, iron overload and cholestasis.
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Hemolytic disease of the fetus and newborn (HDFN) is a con-
dition in which fetal and neonatal erythroid cells are destroyed
by maternal erythrocyte IgG alloantibodies that are trans-
ported across the placenta [1,2]. Maternal alloimmunization
can be triggered by more than 50 different erythrocyte anti-
gens, but most severe cases involve the Rhesus-D antigen
(RhD), which causes Rhesus-mediated hemolytic disease [3].
The effects of the incompatibility of maternal and fetal ery-
throcytes range from anemia and hydrops in the fetus to
hyperbilirubinemia and kernicterus in the newborn [2].
Management of HDFN is therefore a two-way effort, concern-
ing both antenatal as well as postnatal strategies.
The most successful step in antenatal care of HDFN was the
introduction of RhD immunoprophylaxis in 1968 [4]. Before
immunoprophylaxis became available, HDFN affected 1% of all
newborns worldwide and the mortality rate in affected fetuses
was up to 50% [4]. The incidence of Rhesus hemolytic disease
is now approximately 0.5% in RhD-negative women in indus-
trialized countries [2,4]. However, despite adequate RhD
immunoprophylaxis, 1–3 in 1000 RhD-negative women still
develop anti-D antibodies [5]. Antenatal care not only involves
immunoprophylaxis but also the monitoring of high-risk cases
by laboratory testing and ultrasound-based techniques in
order to detect fetal anemia. If necessary, severe fetal anemia
is treated with intrauterine blood transfusions (IUTs) to pre-
vent or treat fetal hydrops [6,7]. At least equally important in
the management of HDFN is postnatal care. Postnatal care
primarily involves the management and stabilization of the
ill and frequently premature newborn [8] but revolves around
the treatment of hyperbilirubinemia and prevention of kernic-
terus by intensive phototherapy and exchange transfusions.
Except for hyperbilirubinemia, other postnatal complications
of HDFN and their respective treatments have been reported
and studied such as early and late anemia. To date, however,
little attention has been devoted to complications such as
thrombocytopenia, iron overload, and cholestasis. The long-
term neurodevelopmental outcome has only recently been
investigated in large cohorts. With the ongoing research on
HDFN, it is important to highlight and summarize recent
developments and to point out the remaining challenges for
the future.
The antenatal treatment of HDFN will be discussed in detail
in this journal in an upcoming review by Zwiers et al. This
review focuses on the current postnatal management and
outcome of HDFN. Recent literature is reviewed and discussed
in a clinical point of view to assess current and future care of
these infants. The main issues addressed in this paper are the
various postnatal treatment options of hyperbilirubinemia and
anemia, as well as long-term outcome.
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2. Management of hyperbilirubinemia
In severe hyperbilirubinemia, unconjugated bilirubin can cross
the blood–brain barrier and can potentially lead to bilirubin
neurotoxicity. A condition defined as bilirubin-induced neuro-
logic dysfunction (BIND) occurs, of which kernicterus or
chronic bilirubin encephalopathy is known as its most severe
and permanent clinical manifestation [9]. In the acute phase of
BIND, symptoms include lethargy, hypotonia, and feeding
problems. Untreated, hyperbilirubinemia can cause fever, a
high-pitched cry, and hypertonia, eventually leading to
apnea, coma, seizures, and death. In kernicterus, the most
affected brain tissues are the basal ganglia, cerebellum, and
various brainstem nuclei. Long-term morbidity in surviving
infants includes athetoid cerebral palsy, hearing loss, and
intellectual disability [10,11].
Standard care of hyperbilirubinemia consists of intensive
phototherapy and, if indicated, exchange transfusions.
Improvement of these treatments remains a constant and
recurring focus of research, as well as the search for alternative
treatments such as pharmacotherapeutic agents that might
enhance treatment of hyperbilirubinemia in HDFN.
2.1. Intensive phototherapy
Since its introduction in the 1970s, phototherapy has been the
main treatment for neonatal hyperbilirubinemia. Phototherapy
causes photo isomerization of bilirubin in the skin to water-
soluble isomers that can be excreted by the kidneys and stool
without further metabolism by the liver. The efficacy of photo-
therapy depends on several factors, including the wavelength
of the light used, the intensity of the light source, the total
light dose (time under phototherapy and amount of skin
exposed), and/or the threshold at which phototherapy is com-
menced [12-15]. The light used in phototherapy needs to
penetrate the skin and be absorbed by bilirubin, which hap-
pens with blue or green light with an optimal wavelength
range of 460–490 nm [12]. The intensity or irradiance (energy
output) of the light source is measured with a radiometer in
units of watts per square centimeter or in microwatts per
square centimeter per nanometer over a given wavelength
band [12]. Light-emitting diodes (LEDs) are the most com-
monly used phototherapy lamps, but also halogen lamps
and fiberoptic systems such as biliblankets are used [10]. A
recent systematic review by Woodgate et al. recommends
close phototherapy (distance of 20 cm above the neonate)
over distant light-source phototherapy (40 cm above the neo-
nate) and double over single phototherapy, thus increasing
the light irradiance. No clear benefit was found for continuous
over intermittent phototherapy in neonates more than 2000 g
or term infants, or for higher skin exposure by removing the
diaper. Phototherapy should be applied once serum bilirubin
levels reach predefined thresholds [15]. In HDFN, the use of
intensive phototherapy is recommended. Intensive photother-
apy is defined by the American Academy of Pediatrics (AAP) as
a spectral irradiance of at least 30 μW per square centimeter
per nanometer over the same bandwidth delivered to as much
of the body-surface area as possible. In practice, intensive
phototherapy is continuous with at least two lamps closely
above the neonate and a biliblanket covering the whole body
and back side of the neonate [10].
Phototherapy is generally considered a safe procedure and
reports of significant toxicity are exceptionally rare and mostly
limited to case reports [10,16]. Recently, two studies were
published on a possible link between phototherapy and devel-
opment of cancer. Specifically, the risk for myeloid leukemia
and kidney cancer seemed slightly increased. However, after
correcting for congenital and chromosomal abnormalities, the
associations were no longer statistically significant [17,18].
Additionally, previous studies could not find an association
between phototherapy and skin cancer [16,19]. Phototherapy
does seem to be associated with the development of allergic
diseases [20].
2.2. Fluid supplementation/hydration
Fluid supplementation during phototherapy may help the
excretion of photoproducts through both urine and bile and
to overcome the increased insensible water loss [21]. However,
with the increased use of LED lights, the beneficial effect of
fluid supplementation in neonates without dehydration
becomes questionable, as LED lights have a much lower heat
output and therefore less insensible water loss [12,14].
Intravenous fluid support has no effect on the rate of decrease
in serum bilirubin and decrease in duration of phototherapy in
healthy term newborns with no dehydration [22,23].
2.3. Exchange transfusion
In the 1940s, treatment of neonatal hyperbilirubinemia with
exchange transfusions was introduced, initially as specific
treatment for Rhesus hemolytic disease [24]. Exchange trans-
fusions lower the serum bilirubin level and remove the anti-
body-coated neonatal erythrocytes and circulating maternal
antibodies to reduce further erythrocyte destruction.
Approximately 85% of the neonatal blood is replaced by
irradiated donor blood double volume exchange transfusion,
which has the additional benefit of providing new albumin
with bilirubin binding sites and directly treating anemia
[25,26]. However, exchange transfusions are not without risk.
Current mortality rates are less than 0.3% in term neonates but
increase above 10% in preterm neonates [27,28]. Morbidity
rates are still high (up to 24%), even in term neonates, and
include cardio-respiratory instability, apnea, catheter-related
complications, thrombocytopenia, and infections [27–29].
There is no clear benefit for the use of single volume
exchange transfusion as opposed to double volume exchange
transfusion; double volume exchange transfusions is current
practice [30]. Two-stage exchange transfusions showed to be
more efficient than one-stage exchange transfusions in term
neonates in single-volume transfusions. In the two-stage pro-
cedure, a first exchange transfusion is given with a 3-h resting
period (allowing for equilibrium of bilirubin to be established
between the intravascular and extravascular compartments),
followed by a second stage. Two-stage exchange transfusion
significantly lowered rebound serum bilirubin and the need
for repeated exchange transfusions. There was no difference in
mortality and morbidity between the two groups [31].
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The frequency of exchange transfusions varies widely
between studies but overall sharply declined since its introduc-
tion due to the emergence of phototherapy, the development
of RhD immunoprophylaxis and improvedmonitoring, and care
for hyperbilirubinemia [28]. Exchange transfusions are now
recommended if bilirubin levels remain above exchange trans-
fusion thresholds despite intensive phototherapy, or if signs of
acute bilirubin encephalopathy occur [10]. The rate of exchange
transfusion in HDFN decreased to around 20% after these more
restrictive guidelines were published by the AAP [10,32].
In our center, the exchange transfusion rate in HDFN
dropped from approximately 70% before 2005 [33] to approxi-
mately 15% thereafter [32]. This reduction was due to the
implementation of a more restrictive guideline for exchange
transfusions in terms of bilirubin cutoff values, especially by
introducing cutoff values for different risk groups, compared
to the more liberal guideline used at our center before 2005.
2.4. Intravenous immunoglobulin
Some studies have shown a reduced need for exchange transfu-
sions in HDFN with the use of intravenous immunoglobulins [34].
Immunoglobulins seem to block Fc receptors on macrophages,
which reduces the breakdown of antibody coated erythrocytes
and lowers the circulating unconjugated bilirubin levels [35].
Administration of intravenous immunoglobulin (0.5–1 g/kg) is
currently recommended by the AAP if the total serum bilirubin
is rising despite intensive phototherapy or the bilirubin level is
within 2–3 mg/dL (34–51 μmol/L) of the exchange level. If neces-
sary, a repeated dose can be given in 12 h [10,34].
Despite current recommendations, a recent randomized
controlled trial by Santos et al. and a recent randomized
controlled trial in our center by Smits-Wintjens et al. could
not support the efficacy of intravenous immunoglobulins in
HDFN [23,36]. As efficacy is questioned, it is important to
point out that although intravenous immunoglobulins are
considered a safe treatment, rare but serious side effects
have been reported, including transfusion transmitted dis-
eases, anaphylaxis, hypersensitivity, thrombosis, pulmonary
emboli, and renal failure [37]. A possible association with
necrotizing enterocolitis (NEC) was found in a retrospective
study comparing near-term infants with Rhesus hemolytic
disease treated with immunoglobulins with a control group
without immunoglobulin treatment [38]. In a meta-analysis
by Yang et al., immunoglobulins showed an increased risk
for NEC (OR 4.53; 95% CI, 2.34–8.79; p < 0.001), but not for
final mortality [39]. A recent systematic review advocates
further well-designed studies before conclusive advice can
be given about the treatment of HDFN with intravenous
immunoglobulins [40].
2.5. Alternatives
Several pharmacotherapeutic agents have been studied as pos-
sible treatment options in neonatal hyperbilirubinemia. The
main focus is on albumin, phenobarbital, metalloporphyrins,
zinc, clofibrate, and prebiotics. None of these agents is currently
recommended as standard care in hyperbilirubinemia [10].
2.5.1. Albumin
As albumin binds bilirubin, it is thought that extra adminis-
tered albumin can lower serum bilirubin levels. However,
sufficiently powered trials on the clinical benefits are lacking
and albumin administration is not recommended as stan-
dard care at this moment [10]. A small randomized con-
trolled trial in India by Shahian et al. showed evidence that
albumin administration prior to exchange transfusion is
beneficial to lower total serum bilirubin levels post
exchange and lower the mean duration of phototherapy
[41]. A subsequent randomized controlled trial did not
show the same effects [42]. The AAP marks it as an option
to measure the serum albumin level in neonates with
hyperbilirubinemia and to consider an albumin level below
3.0 g/dL as an extra risk factor to lower the phototherapy
threshold. Furthermore, if an exchange transfusion is being
considered, the serum albumin level should always be mea-
sured and with the bilirubin/albumin ratio used in determin-
ing the need for exchange transfusions. Albumin
supplementation is not recommended [10].
2.5.2. Phenobarbital
Phenobarbital was used in an attempt to increase biliary
flow in the 1970s. Phenobarbital increases hepatic uridine
diphosphate (UDP)-glucuronosyl transferase (UGT) activity
and the conjugation of bilirubin and has a possible positive
effect on hepatic uptake of bilirubin [43,44]. A recent ran-
domized clinical trial by Kaabneh et al. in neonates with
HDFN showed a minor advantage of adding phenobarbital
to phototherapy treatment [45]. However, phenobarbital
acts slowly and is therefore not the treatment of choice
when adequate phototherapy and exchange transfusions
are available. There might be a role for antenatal maternal
administration of phenobarbital, as positive results
(decreased need for exchange transfusions) were found in
a retrospective study by Trevett et al., although these
results are yet to be confirmed [46].
2.5.3. Metalloporphyrins
Metalloporphyrins inhibit heme-oxygenase, the rate-limiting
enzyme in the catabolism of heme to bilirubin. In this manner,
metalloporphyrins decreases the production of bilirubin,
rather than increasing the excretion of bilirubin [47].
Treatment with metalloporphyrins may reduce neonatal bilir-
ubin levels and decrease the need for phototherapy and
hospitalization. Sufficient evidence is lacking however to
recommend routine treatment of hyperbilirubinemia with
metalloporphyrins [48].
2.5.4. Zinc
Oral zinc is thought to reduce the serum bilirubin by decreas-
ing the enterohepatic circulation of bilirubin [49]. However,
recent systematic reviews by Mishra et al. and Sharma et al.
concluded that there is currently no role for zinc in the treat-
ment of neonatal hyperbilirubinemia. There seems to be no
effect on duration of phototherapy, incidence of photother-
apy, or age of starting of phototherapy [50,51].
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2.5.5. Clofibrate
Clofibrate induces glucuronosyl transferase that changes bilir-
ubin in a water-soluble form that can be excreted. It seems
that clofibrate in combination with phototherapy lowers the
level of bilirubin and shortens the duration of phototherapy in
term neonates [52,53], but larger trials are needed to evaluate
its effect. Further research is especially needed in hemolytic-
caused hyperbilirubinemia, as these neonates were excluded
in some of the trials [54].
2.5.6. Prebiotic supplementation
Recently, the role of prebiotic supplementation was focus for
research on the treatment of neonatal hyperbilirubinemia.
Prebiotics are thought to increase gastrointestinal motility
and stool frequency, decrease viscosity of stool and the enter-
ohepatic circulation of bilirubin, and improve feeding toler-
ance and growth of beneficial bacteria in the gut. Results
seem promising in both preterm and term neonates with
hyperbilirubinemia on total serum bilirubin levels as well as
duration of phototherapy [55,56].
2.5.7. Antenatal corticosteroids
Antenatal treatment with corticosteroids has been shown to
accelerate lung maturation in preterm infants and reduce the
risks of respiratory disorders, especially in those born before
34-week gestation [57]. Although antenatal betamethasone
given after 34-week gestation does not appear to decrease
the risk of respiratory disorders, recent studies reveal that
betamethasone reduces the risk of neonatal jaundice requir-
ing phototherapy, possibly because of acceleration of liver
maturation [58]. A randomized controlled trial comparing
antenatal steroids to conventional treatment will be carried
out in our center in the near future.
3. Management of anemia
Hemolysis of the fetal erythrocytes by maternal alloantibodies
causes anemia. These alloantibodies remain in the neonatal
circulation after birth for several months and can cause pro-
longed anemia. Anemia in hemolytic disease is divided in early
anemia (onset at birth up to 7 days of age) and late anemia. Late
anemia occurs in 83% of neonates of a gestational age of
35 weeks or more with HDFN and is further split into ‘late
hyporegenerative anemia’ and ‘late anemia of hemolytic dis-
ease’ [59]. Late hyporegenerative anemia is caused by
depressed erythropoiesis and is characterized subsequently
by low reticulocyte counts. Underlying mechanisms are pro-
posed to be the following: intramedullary destruction of ery-
throcyte precursors, bone marrow suppression from
intrauterine and postnatal transfusions, erythropoietin (EPO)
deficiency; shortened half-life of transfused erythrocytes, and
relative anemia due to the expanding intravascular volume of
the growing neonate. Late anemia of hemolytic disease is
characterized by age-appropriate or elevated reticulocyte
counts, reflecting an active bone marrow to compensate for
the shortened erythrocyte survival. This form of late anemia is
thought to be due to a combination of continuing hemolysis by
remaining antibodies, shortened survival of transfused
erythrocytes, natural decline of the hemoglobin level, and the
expanding intravascular volume of the growing neonate
[59,60].
Interestingly, although late anemia was already described
before IUTs were available, IUTs seem to actually increase the
risk of postnatal anemia. The pathophysiological mechanism is
not entirely understood, but treatment with repeated IUTs
possibly lead to persistent anemia due to suppression of
erythropoiesis [33].
Primary treatment of anemia in HDFN is administering
erythrocyte transfusions, known as top-up transfusions. In
addition, several pharmacological agents are used to stimulate
erythropoiesis.
3.1. Top-up transfusions
Late anemia usually resolves by the third month of life; until
then, erythrocyte transfusions may be necessary to treat post-
partum anemia [59,61]. The mean postnatal age for a first top-
up transfusion in HDFN is 18 days (range 1–34) [62]. At least
one top-up transfusion is reported to be required in 68–83%
of neonates with HDFN [33,59,63]. Some neonates need up to
six top-up transfusions in the first 3 months of life [62]. In
neonates that were treated with IUTs, the top-up transfusion
rate is significantly higher (77–89%), than in neonates that
were not treated with IUTs (27–67%) [33,59,63]. In the IUT
group, the median number of top-up transfusions was 1
(range, 0–4), compared to 0 (range, 0–2) in non-IUT group
(p < 0.01) [33]. This difference can be explained by a depressed
erythropoiesis and is correlated with a significantly lower reti-
culocyte count at birth in transfused neonates [33,62,64].
Variations in the percentage of neonates requiring top-up
transfusions may be explained by various factors, including
differences in transfusion guidelines and thresholds for ery-
throcyte transfusions. In our center, a top-up transfusion of
15 mL/kg irradiated erythrocytes is indicated in term neonates
with HDFN when hemoglobin levels fall below 7.2 g/dL
(4.5 mmol/L) or below 8.8 g/dL (5.5 mmol/L) when clinical
symptoms of anemia are present (increased oxygen need,
poor feeding, tachycardia, and/or tachypnea).
3.2. Exchange transfusion
Exchange transfusions not only have a positive effect on the
clearance of bilirubinemia in hemolytic disease, but as men-
tioned before, but it also treats anemia as the neonatal blood
is replaced by immunologically compatible donor blood and
decreases plasma ferritin and iron levels [25]. The reduced
need for exchange transfusion in the last decades seems to
be associated with an increased need for top-up transfusions.
This is probably explained by longer lasting hemolysis due to a
reduced clearance of maternal antibodies [33,63].
3.3. Delayed cord clamping
Delayed cord clamping at birth allows additional placental
blood transfusion. In a term newborn, this transfusion can con-
sist up to one-quarter to one-third of the total neonatal blood
volume [65]. In anemia secondary to erythrocyte
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alloimmunization, a significant increase in hemoglobulin levels
at birth was observed, as well as a longer delay between birth
and first transfusion, and a decrease in the number of postnatal
exchange transfusions, with no notable adverse effects [66,67].
3.4. Pharmacotherapeutic options
In erythropoiesis, sufficient amounts of EPO, folate, iron, and
vitamin E are essential. To enhance erythropoiesis, administra-
tion of these nutrients may have a beneficial effect in the
treatment of anemia in HDFN [68,69].
3.4.1. EPO
EPO is the principle growth factor responsible for fetal and
neonatal erythropoiesis and is primarily developed in the
fetal liver [70], since over a decade, recombinant human
EPO has been applied in small studies and casuistic reports,
with different outcomes for the occurrence of anemia and
the need for top-up transfusions in neonates with HDFN
[71–74]. Due to limited clinical importance of observed
beneficial effects, routine use of EPO is currently not recom-
mended [75]. A well-designed randomized controlled clin-
ical trial of sufficient sample size is required to establish the
role of EPO in the treatment of HDFN [69] and will be
carried out in our center in the near future. In this trial,
included neonates will be randomized at birth to treatment
with darbepoetin or conventional care. The intervention
group will receive darbepoetin subcutaneously once a
week in 10 U/kg/dose for 8 weeks.
3.4.2. Folate
Folate plays a role in the proliferation of erythroblasts during
their differentiation [68]. Very limited data are available on its
therapeutic efficacy, although a small effect has been seen in
the addition of both vitamin B12 (3 µg/kg/day) and folate
(100 µg/kg/day) to EPO as treatment in anemia of prematurity
[76]. Due to the prolonged anemia often seen in HDFN, folate
is supplemented in our center for 3 months postpartum in a
dosage of 250 µg/day.
3.4.3. Iron
Iron is required for hemoglobin synthesis by erythroblasts.
The use of iron in anemia associated with HDFN has been
studied most extensively in combination with EPO.
Administration of EPO without, or with, low iron supple-
mentation can lead to iron deficiency and ineffective ery-
thropoiesis [69,77]. However, neonates with HDFN tend to
have an iron overload due to the combination of prolonged
hemolysis and treatment with multiple IUTs and erythrocyte
transfusions. Based on current knowledge, iron supplemen-
tation should be withheld, especially in transfused infants as
it is associated with numerous potential adverse effects
[78,79].
3.4.4. Vitamin E
It is unclear whether vitamin E acts as an antioxidant that
protects the erythrocyte membrane or as an erythropoietic
factor, but shortage of vitamin E might be an additional
cause of anemia [80]. Limited data are available on the
therapeutic effects of vitamin E. A pilot study of Pathak et al.
showed that oral supplementation at 50 IU/day does not
enhance the response of preterm neonates to EPO and iron,
compared to placebo [81].
4. Management of other complications
4.1. BIND and kernicterus
Although rare, BIND and kernicterus are still occurring in the
industrialized world. According to rough estimates based on
national registration systems, a severely high bilirubin count
(>420 µmol/l) occurs in 100–200 infants a year in the
Netherlands (i.e. 0.5–1 per 1000 live births). Although
cases of kernicterus are reported several times a year, pre-
cise estimates on the prevalence of kernicterus are not
available [82]. Alarmingly, throughout the 1990s, a signifi-
cant rise in case reports of kernicterus occurred compared
to previous years. This rise was attributed to a combination
of reduced concern for jaundice in newborns, early dis-
charge with inadequate follow-up and a decreased aware-
ness of the long-term complications of hyperbilirubinemia
and guidelines were updated and implemented accordingly
[83]. Cornerstone of the management of BIND and kernic-
terus is timely and adequate treatment of hyperbilirubine-
mia. Rather than applying phototherapy and exchange
transfusions when necessary, the treatment of hyperbiliru-
binemia is a complex interplay of adequate screening of at-
risk pregnancies, anticipation of the hyperbilirubinemic
neonate, and the combination of antenatal and postnatal
management. The importance of this interplay is also
reflected in the nonlinear relationship between neonatal
bilirubin levels and the risk of BIND and kernicterus and
the wide variety of clinical manifestations, varying between
neurodevelopmental difficulties (including developmental
delay, cognitive impairment, and disordered executive func-
tion), and behavioral and psychiatric disorders [84].
4.2. Thrombocytopenia
In severe HDFN, thrombocytopenia is believed to be caused
by increased erythropoiesis as it can suppress the other cell
lines and potentially cause leucopenia and thrombocytopenia
[85]. A retrospective study in our center showed a 26% inci-
dence of thrombocytopenia (platelet count <150 × 109/L) in
neonates treated with IUT for Rhesus D hemolytic disease. The
occurrence of thrombocytopenia was an independent risk
factor for perinatal mortality [86]. A more recent retrospective
observational study was carried out in our center and also
showed a similar incidence of 26% of thrombocytopenia in all
neonates with HDFN at birth. Severe thrombocytopenia was
found in 6% of neonates. Three risk factors were indepen-
dently associated with thrombocytopenia at birth: treatment
with IUT, being born ‘small-for-gestational-age’ (defined as a
birth weight below the 10th percentile) and lower gestational
age at birth [87]. Thrombocytopenia in HDFN is usually a self-
limiting disease but treatment with platelet transfusions may
be needed if platelets drop below transfusion threshold.
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4.3. Iron overload
As mentioned before, neonates with Rhesus hemolytic disease
tend to have an iron overload. This is caused by the combina-
tion of prolonged hemolysis and treatment with multiple IUTs
and erythrocyte transfusions [72,73,88]. Although iron is essen-
tial in early brain development and function, iron overload can
have detrimental health effects as well. It causes damage to
the liver, heart, and endocrine organs, alters immune
response, and increases susceptibility to infection [89]. Iron
deficiency in the first 3 months of life is very rare in HDFN
and has not been described in neonates that received post-
natal top-up transfusions. Iron overload occurs in 70% of
neonates with HDFN at birth, 50% at the age of 1 month
and 18% at the age of 3 months. In neonates with HDFN
that received IUTs, ferritin levels were twice as high compared
to controls at birth (mean 598 ± 249 vs. 270 ± 111 µg/L,
p < 0.001) [73]. The use of iron supplementation in the first
3 months of life in neonates with severe HDFN is strongly
discouraged, particularly after IUTs.
4.4. Cholestasis
Conjugated hyperbilirubinemia (cholestasis) has been
described in neonates with HDFN [90,91] and can give rise
to suspicion of underlying liver disease with additional diag-
nostic measures. A retrospective study in our center showed a
total incidence of cholestasis in infants with RHDN of 13% (41/
313). Cholestasis in hemolysis might be caused by obstruction
of the excretory system by excessive conjugated bilirubin and
should primarily be regarded as complication of HDFN.
Treatment with one or more IUT and RhD alloimmunization
were independent risk factors for cholestasis. Cholestasis
resolved spontaneously within 1 week–3 months after birth
in almost half of the patients, but the authors advocate larger
studies to confirm these findings and to determine the exact
course and etiology of cholestasis in HDFN [92].
5. Long-term outcome
With the improvements in antenatal and neonatal management
over the past decades, survival has significantly improved in
HDFN. As mortality rates are lower, attention is shifting toward
the long-term outcome in the surviving neonates. Adverse pre-
natal conditions including impaired fetal nutrition and growth
can have a profound and long-lasting impact on physical and
mental health throughout life, for example increased risk of
cardiovascular disease, neuropsychological disorders, and meta-
bolic disease [93,94]. The impact of severe fetal and neonatal
anemia, hyperbilirubinemia and of the (invasive) procedures and
treatments fetuses and neonates with HDFN are exposed to is
unknown but seem to justify long-term follow-up studies as
current data are limited [95].
5.1. Long-term outcome after IUT
A large long-term follow-up study in our center, the LOTUS study
(Long-Term follow-up after intra-Uterine transfusionS), was per-
formed to determine the incidence of neurodevelopmental
impairment (NDI) in children treatedwith IUT for HDFN (between
1988 and 2008). A total of 291 children were studied at a median
age of 8.2 years. NDI was defined as the presence of one or more
of the following: cerebral palsy, severe developmental delay,
bilateral blindness, and/or deafness. The incidence of severe
NDI was 3.1%, comparable to the Dutch normative population
(2.3%). The overall rate of NDI was 4.8% (14/291). In amultivariate
regression analysis, the number of IUTs, severe neonatal morbid-
ity, parental education, and severe prenatal hydrops were inde-
pendent risk factors associated with NDI [96].
Health-related quality of life and behavioral functioning in
285 children and adolescents treated with IUT for alloimmune
anemia was recently assessed at our center [97]. Parents
reported lower scores on cognitive functioning in their chil-
dren aged 6–11 years compared to Dutch norms. Behavioral
difficulties were more prevalent than norms and associated
with maternal educational level. Overall, in the majority of
survivors, long-term outcome following IUT for alloimmune
anemia appears favorable.
Hypothetically, the chronic anemia caused by immune
hemolysis in the fetus results in the need for increased cardiac
output and may lead to myocardial hypertrophy. Limited data
show that HDFN treated with IUT may lead to less myocardial
mass in childhood, but the long-term cardiovascular conse-
quences in adult life are unknown [95]. However, very recently,
a retrospective cohort study by Wallace et al. was published
on the cardiac function and cardiovascular risk factors in
adults exposed to fetal anemia and intrauterine transfusion
(n = 95), compared to their healthy siblings. The former
patients showed smaller left ventricular volumes, increased
left ventricular wall thickness, and decreased myocardial per-
fusion at rest, concluding that cardiovascular development is
altered after exposure to fetal anemia and IUT. It is unknown
whether this will have clinical consequences regarding the
development of cardiovascular disease as the average age at
the time of study was 34 years [98].
5.2. Long-term outcome after immunoglobulins
In a follow-up study of a randomized controlled trial con-
ducted at our center, we found that the neurodevelopmental
outcome in children treated with intravenous immunoglobu-
lins for HDFN was not different from children treated with
placebo [32,99]. At a median age of 4 years, NDI was detected
in 3% in both the IVIG (1/34) and placebo (1/32) group. After
stratification for treatment with or without IUT, similar results
were obtained. Standardized long-term follow-up studies with
large enough case series and sufficient power are needed to
replicate these findings.
6. Conclusion
Over the years, neonatal management and outcome in HDFN
improved significantly. Classical therapies such as intensive
phototherapy and exchange transfusions for hyperbilirubine-
mia and erythrocyte transfusions for anemia are well studied
but are still improved upon. Alternative treatments have been
suggested such as albumin, phenobarbital, metalloporphyrins,
zinc, clofibrate, and prebiotics in hyperbilirubinemia and EPO,
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folate, iron, and vitamin E in anemia. These alternative agents
have varyingly been studied but lack evidence to support their
use. Although long-term outcome in HDFN seems favorable,
neonates with fetal hydrops have a general bad outcome. This
emphasizes the need for adequate screening and treatment,
preferably regulated by nationwide guidelines and
monitoring.
7. Expert commentary
Our clinical experience, as a tertiary referral center of
Neonatology, is in line with the conclusions reported above.
The Leiden University Medical Center is the national referral
center for HDFN in the Netherlands, which allowed us to
develop as an expertise center and to play an important role
nationwide in the care for these neonates. Despite major
advances in the field of HDFN, multiple issues still need to
be addressed in the future to optimize the postnatal manage-
ment of neonates with HDFN.
First, it is important to emphasize that major improvements
could probably be achieved by strict adherence to guidelines.
Clear guidelines on screening and management appear to
have significant effect but have to be evaluated continuously
and implemented around the globe. Strict adherence to
guidelines is recommended to further eradicate kernicterus
and treat affected fetuses and neonates effectively.
Second, to further assess the extent of the problems in the
management of HDFN, it is important to assess its epidemio-
logic aspect. We need exact and national numbers on the
occurrence of hyperbilirubinemia, exchange transfusions and
kernicterus as well as insight in clinical course and pitfalls in
these cases. To better asses these cases, the pathophysiologic
mechanisms also have to be better understood. For example,
not much is known on BIND and why some infants develop
kernicterus and others with an equally high serum bilirubin do
not. It is also unclear what the exact mechanism of late anemia
is and why some neonates require top-up transfusions up to
3 months of life.
Third, pharmacotherapeutic agents should be further
researched as potential alternatives for and supplements to
classical treatments. As pointed out, the role of albumin sup-
plementation (prior to exchange transfusion), phenobarbital
(especially antenatal maternal administration), metallopor-
phyrins, zinc, clofibrate, and prebiotics in hyperbilirubinemia
needs to be clarified. Prospective, double-blinded RCTs are
necessary to evaluate outcome and adverse effects, ideally in
HDFN-specific patient groups. The use of immunoglobulins in
Rhesus haemolytic disease should be re-evaluated on efficacy
and safety in the prevention of exchange transfusions. Larger
trials are warranted to evaluate the use of EPO, folate, and
vitamin E in neonates with HDFN in the treatment of postnatal
anemia. Due to the low occurrence rate of HDFN, these trials
should be multicenter international studies to reach sufficient
power.
Lastly, there is a general lack of long-term follow-up studies
in HDFN. Especially, complications such as thrombocytopenia,
iron overload, and cholestasis should be studied in terms of
short-term and long-term effects.
The ultimate goal in HDFN is timely detection and treat-
ment of maternal alloimmunization in an effort to lower the
occurrence of hyperbilirubinemia and to completely eradicate
kernicterus, with a prosperous long-term prognosis for all
affected neonates.
8. Five-year view
Detection and management of HDFN have vastly improved in
the last decades. Unfortunately, it is still a major cause of
hyperbilirubinemia and, on occasion, kernicterus. The eradica-
tion of kernicterus has been a worldwide point of interest and
can partly be achieved by adequate management of neonates
with HDFN. By strict compliance to national guidelines, HDFN
can be timely recognized and treated. It would be desirable in
the future to obtain more information of the associations
between serum bilirubin levels and neurologic damage, as
well as epidemiologic information. Much attention is currently
focused at identifying new pharmacological agents in HDFN.
Some of these have already been used in clinical practice;
others are currently under evaluation or await proper
designed trials. Studies are needed on the impact of treatment
in the long-term follow-up.
Key issues
● Despite RhD immunoprophylaxis, 1 to 3 in 1000 RhD nega-
tive woman develop anti-D antibodies, therefore HDFN is
still a relevant condition of which treatment needs to be
optimized.
● Guidelines for hyperbilirubinemia and specifically for this
group should be implemented worldwide and strictly
followed.
● Intensive phototherapy and exchange transfusions are the
treatment of choice in hemolytic hyperbilirubinemia,
although alternative pharmacotherapeutic agents are
researched.
● Late anemia is a common problem in neonates with HDFN
and can last up to three months of age. In Rhesus hemolytic
disease the majority of neonates needs at least one to up to
six top-up transfusions.
● HDFN is associated with postnatal thrombocytopenia, iron
overload and cholestasis.
● Limited studies are available on long-term outcome in
HDFN, but generally show a favorable outcome in neonates
that did not develop kernicterus.
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